Internal Medicine, Nephrology · Grove City, OH
NPI
1174531354
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
6
Hospital affiliations
5775 N Meadows Dr Ste D
Grove City, OH, 43123
Phone (614) 224-4200
Groups this clinician bills Medicare through
Medicare paid, 2024
$112K
1,493 services
Medicare patients, 2024
395
Average age 74
Drug cost, 2024
$494K
2,984 prescriptions
Company payments, 2025
$354
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin P O'Reilly was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 393 times for 216 patients. In total Kevin P O'Reilly billed 1,493 services in 22 codes, and Medicare paid $112K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-12.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 393 | 216 | $12.11 | $4,761 |
| 99214 Office E&M - Established | Office | 230 | 173 | $55.11 | $13K |
| 99215 Office E&M - Established | Office | 178 | 116 | $73.35 | $13K |
| 99233 Hospital E&M - Subsequent | Facility | 138 | 78 | $86.88 | $12K |
| 99232 Hospital E&M - Subsequent | Facility | 133 | 77 | $56.92 | $7,571 |
| 90960 ESRD Related Services (not dialysis) | Office | 102 | 18 | $257.64 | $26K |
| 90935 Hemodialysis | Facility | 69 | 44 | $53.42 | $3,686 |
| 99223 Hospital E&M - Initial | Facility | 68 | 64 | $123.54 | $8,400 |
| 90961 ESRD Related Services (not dialysis) | Office | 31 | 19 | $214.46 | $6,648 |
| 99205 Office E&M - New | Office | 28 | 28 | $166.47 | $4,661 |
| 99291 Critical Care E&M | Facility | 24 | 13 | $161.08 | $3,866 |
By year: 2022 $104K for 1,125 services; 2023 $94K for 1,086 services; 2024 $112K for 1,493 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81000 Clinical Chemistry | 11 | 11 | $3.98 | $43.78 |
Medicare prescription drug claims, 2024
In 2024, the drug Kevin P O'Reilly prescribed most often to Medicare patients was Chlorthalidone, with 364 prescriptions and refills. In total Kevin P O'Reilly wrote 2,984 Medicare prescriptions that cost $494K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Chlorthalidone Generic | 364 | 1,007 | 114 | $7,886 |
| Amlodipine Besylate Generic | 244 | 685 | 85 | $1,685 |
| Lisinopril Generic | 196 | 560 | 65 | $1,331 |
| Farxiga Dapagliflozin Propanediol | 175 | 349 | 42 | $192K |
| Allopurinol Generic | 158 | 391 | 40 | $1,346 |
| Spironolactone Generic | 144 | 378 | 53 | $1,286 |
| Losartan Potassium Generic | 138 | 409 | 56 | $1,446 |
| Carvedilol Generic | 138 | 365 | 45 | $2,073 |
| Metoprolol Succinate Generic | 125 | 367 | 43 | $2,206 |
| Calcitriol Generic | 91 | 239 | 31 | $1,538 |
| Valsartan Generic | 88 | 227 | 31 | $3,042 |
| Torsemide Generic | 88 | 241 | 34 | $1,760 |
| Olmesartan Medoxomil Generic | 84 | 236 | 29 | $2,413 |
| Furosemide Generic | 78 | 182 | 28 | $468 |
| Jardiance Empagliflozin | 74 | 132 | 25 | $76K |
Brand drugs: 387 claims; generic drugs: 2,597 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin P O'Reilly $354 ($354 in general payments such as food, travel and fees) from 7 companies. The largest payer was Amgen Inc. with $143.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.